|
Orthologous residues
|
|
RhoGDI alpha (human): S34‑p, RhoGDI alpha iso3 (human): S34‑p, RhoGDI alpha (mouse): S34‑p, RhoGDI alpha (rat): S34‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site, phospho-antibody, western blotting
|
|
Disease tissue studied:
leukemia, chronic myelogenous leukemia
|
|
Relevant cell lines - cell types - tissues:
K562 (erythroid), MDCK (epithelial), S2
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
dog, fruit fly, human
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
phorbol ester
|
|
|
|
increase
|
|
|
Go 6976
|
phorbol ester
|
|
|
inhibit treatment-induced increase
|
|
|
GF109203X
|
phorbol ester
|
|
|
inhibit treatment-induced increase
|
|
|
HGF
|
|
|
|
increase
|
|
|
Go 6976
|
HGF
|
|
|
inhibit treatment-induced increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
molecular association, regulation
|
|
Effect of modification (process):
cell adhesion, altered
|
|
Modification regulates interactions with:
|
|
Interacting molecule
|
Interacting domains
|
Effect
|
Consequences (function)
|
Consequences (process)
|
Detection assays
|
|
RhoA (human)
|
|
Disrupts
|
|
|
pull-down assay
|
|
